Tissue Genesis begins trials for PVD using ASCs

Wednesday, April 20, 2011 12:15 PM

Tissue Genesis, a company focused on adult stem cell and regenerative medicine, has begun clinical trials for peripheral vascular disease (PVD) with adipose-derived adult stem cell-coated vascular grafts at the University of Louisville hospital.  Tissue Genesis is the first to initiate a FDA-approved trial using the patient's own adipose-derived adult stem cells (ASCs) prepared at the point-of-care. 

Tissue Genesis uses a Cell Isolation System which is a compact, automated desktop unit that utilizes liposuctioned adipose tissue to isolate millions of adult stem cells in about an hour.  This proprietary enabling platform technology averages approximately 35 to 50 million stromal cells per 60 cc of adipose, which then can be potentially applied to a variety of unmet medical needs.  The point-of-care Cell Isolation System, manufactured to the highest standards, is CE-marked and GMP-certified.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs